Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# MucosaTec GmbH

## Sitemaps

- [XML Sitemap](https://www.mucosatec.eu/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://www.mucosatec.eu/news/)
- [Taking the Threat of H5N1 Seriously - Developing Solutions](https://www.mucosatec.eu/taking-the-threat-of-h5n1-seriously-developing-solutions/) - The avian flu H5N1 has claimed a human life in the USA. A stark reminder of how real the danger of future pandemics is.
- [MucosaTec GmbH Wins SPRIN-D Challenge](https://www.mucosatec.eu/mucosatec-gmbh-wins-sprin-d-challenge/) - MucosaTec's Groundbreaking Platform Technology Wins Broad-Spectrum Antiviral Challenge After Years of Pioneering Research.
- [MucosaTec GmbH sponsors VBBN Meeting](https://www.mucosatec.eu/mucosatec-gmbh-sponsors-vbbn-meeting/) - MucosaTec GmbH sponsors Virus Biology and Biophysics Network Meeting supporting scientists in fostering scientific exchange and collaboration.
- [Novel Idea for antiviral Nasal Spray on Tagesspiegel.de](https://www.mucosatec.eu/tagesspiegel-features-us-again/) - Novel Nasal Spray is presented on Tagesspiegel.de The MucBoost research project is based on completely new approach to fight viruses and aimes to develop an easy to use antiviral nasal spray.
- [Thorough article on Tagesspiegel.de](https://www.mucosatec.eu/tagesspiegel-features-us/) - MucosaTec reports article on Tagesspiegel.de about MucBoost research project
- [Winning Teams of reseach challenge](https://www.mucosatec.eu/winning-teams-of-reseach-challenge/) - A detailed report on three winners of the challenge from SPRIND - the Federal Agency for Disruptive Innovation - Germany on the topic of "broad-spectrum antivirals" appears in the blog of the magazine "Laborjournal". The first thing in the article is to introduce and explain Dr. Daniel Lauster and his research project at the Freie Winning Teams Sprind antivirals challenge
- [Informative article for German Pharmacists](https://www.mucosatec.eu/pharmacists-get-informed/) - The newspage of the German Pharmacist Association (Pharmazeutische-Zeitung.de) features the the first level of the challenge „broad-spectrum antivirals“ by SPRIND – the Federal Agency for Disruptive Innovation – Germany with an article. Among the nine teams is the MucBoost project, from which MucosaTec GmbH is a spin-off. Pharmazeutische-Zeitung.de counted 3,470,205 page impressions and 1,733,170 visits German Pharmacist Association
- [Popular Son of his Hometown](https://www.mucosatec.eu/popular-son-of-his-hometown/) - The local newspaper "Der Teckbote" has an affectionate report about a son of the city Kirchheim unter Teck - Dr. Daniel Lauster. The founding of his research group at the Freie University of Berlin and his "unappetizing" research topics are reported in detail. As unappetizing - with a wink - they mention the general research Son of his Hometown Dr. Daniel Lauster
- [Finalist to pitch at the BARDA VITAL Global Health Security Symposium](https://www.mucosatec.eu/finalist-to-pitch-at-the-barda-vital-global-health-security-symposium/) - We are thrilled to announce that we have been selected as a finalist to pitch at the BARDA VITAL Global Health Security Symposium on June 27 in Berlin.This event focuses on visionary advancements in vaccine and therapeutics innovation, and medical countermeasures aimed at enhancing pandemic preparedness and response for a safer future.Join us as we
- [Start-up Prize of Science & Startups Berliner Sparkasse](https://www.mucosatec.eu/start-up-prize-of-science-startups-berliner-sparkasse/) - ‍Last week, Marius Hittinger represented MucosaTec at the Start-up Prize of Science & Startups Berliner Sparkasse. He presented our technology, business model, financing strategies and development opportunities to an expert panel. The Berliner Sparkasse Prize is awarded annually and is a significant milestone for the university-based startup scene in Berlin. The best teams formed over the past year from the
- [MucosaTec nominated for “Science & Start-Ups – the Berliner Sparkasse Founders Award”](https://www.mucosatec.eu/mucosatec-nominated-for-science-startups-the-berliner-sparkasse-founding-prize/) - This first edition of the founders award will be awarded on June 26th, 2024 from 6:00 p.m. in the beautiful premises of the "Berliner Sparkasse am Wannsee" (Kronprinzessinnenweg 21). An event in this constellation marks a significant milestone for Berlin's university start-up scene and shows the enormous potential that exists in Berlin. The best nine
- [Bionity.com about us winning BioRegions Innovation Prize](https://www.mucosatec.eu/bionity-com-about-us-winning-bioregions-innovation-prize/) - Bionity.com reports in the news about MucosaTec winning the Innovation Award 2024. MucosaTec's technology comprises novel bifunctional peptides that provide a flexible and cost-effective method of combating viral infections. The peptides bind to both the pathogen and the mucus, our body's natural barrier, and thus immobilize pathogens. This innovation could form the basis for the
- [Berliner Zeitung about us winning BioRegions Innovation Prize](https://www.mucosatec.eu/berliner-zeitung-about-us-winning-bioregions-innovation-prize/) - A major daily newspaper in Berlin, Germany, the “Berliner Zeitung”, reports on its homepage about MucosaTec winning the Innovation Award 2024. The BioRegions prize is awarded for outstanding research results and inventions with high innovation potential. MucosaTec's technology comprises novel bifunctional peptides that provide a flexible and cost-effective method of combating viral infections.
- [YouTube video about the science behind our product](https://www.mucosatec.eu/youtube-video-about-the-science-behind-our-product/) - Learn more about the science behind our nasal spray in this video. The YouTube channel "Breaking Lab" presents the team MucBoost and other teams of the challenge "broad-spectrum antivirals", which was launched by SPRIND, the Federal Agency for Disruptive Innovation - Germany. The MucBoost project is one of the winners of the challenge's second stage
- [MucosaTec at Venture SPRIND 2024](https://www.mucosatec.eu/mucosatec-at-venture-sprind-2024/) - MucosaTec was invited to Venture SPRIND 2024 in Berlin on April 24th, 2024. The event will bring together over 300 business angels, VCs, and venture debt investors to meet 45 teams from the SPRIND portfolio. The presence of political guest Robert Habeck, German Federal Minister for Economic Affairs and Climate Action, adds even more significance
- [MucosaTec wins BioRegions Innovation Prize 2024](https://www.mucosatec.eu/mucosatec-wins-bioregions-innovation-prize-2024/) - The esteemed BioRegions Innovation Prize 2024 was proudly presented to the MucosaTec team. Our groundbreaking patent for bifunctional peptides showcases a revolutionary technology that offers a flexible and cost-effective approach to combating viral infections. These peptides bind to both pathogens and our mucus, effectively immobilizing pathogenes. The award ceremony for this prestigious recognition took place
- [Talents with potential](https://www.mucosatec.eu/talents-with-potential/) - MucosaTec GmbH is presented in the Journal "Potenzial" (english: Potential) in the section "Talente" (english: Talents). The Journal is published by the Company WISTA owned by the city of Berlin. MucosaTec GmbH is presented in a comprehensive article covering the scientific basis, Prof. Lauster and his team, locations of the start-up in Berlin and the
- [Our Project on the official Homepage of SPRIND](https://www.mucosatec.eu/our-project-on-the-official-homepage-of-sprind/) - MucosaTec GmbH was created as a spin-off of the MucBoost project. In the challenge „broad-spectrum antivirals“ by SPRIND - the Federal Agency for Disruptive Innovation - Germany, our project MucBoost was one of the winners of the third stage. The official Homepage presents pictures of some team members at work in our beautiful labs and
- [Our research hits it big - again](https://www.mucosatec.eu/our-research-hits-it-big-again/) - The Newspage of the 5th biggest national Newspaper in Germany – Welt – presents our research and the planned product in another big article (Welt+ required). The topic is wrapped different this time to fit in their "Health" section relating to the beginning of flu-season in Germany. Estimated 1.4 million readers are reached with the
- [Our research hits it big](https://www.mucosatec.eu/our-research-hits-it-big/) - November is flu-season in Germany. Therefore the 5th biggest national Newspaper in Germany – Welt – got the great idea to present our research and the planned product in a big article in their "Knowledge" section of the printed version. Estimated 1.4 million readers are reached with the printed paper and the web services of
- [We are thrilled to announce that MucosaTec has been nominated for the Innovation Prize 2024!](https://www.mucosatec.eu/we-are-thrilled-to-announce-that-mucosatec-has-been-nominated-for-the-innovation-prize-2024/) - MucosaTec is among the final six candidates for this year's Innovation Prize of the BioRegions in Germany, which aims to promote the economic utilization of modern biotechnologies. We will be presenting at the German Biotech Days on the 16th of April in Berlin and are incredibly excited to be part of this journey.
- [MucosaTec GmbH was founded](https://www.mucosatec.eu/avoiding-trends-and-staying-true-to-the-principles/) - Today we finally founded the company!

## Pages

- [Home](https://www.mucosatec.eu/) - Boosting the natural barrier function of mucus MucosaTec GmbH - The mucus engineering company improves human mucus to fight pathogens Mucosatec As Team MucBoost we reached the final stage of the SPRIND Challenge: “Broad Spectrum Antivirals” If we overcome the weakness of mucus with virus-binding proteins, we will equip mucus with an evolutionary upgrade. -
- [About us](https://www.mucosatec.eu/about-us/) - Our Work Want to get more information? Please do not hesitate to contact us Contact Us
- [Pipeline](https://www.mucosatec.eu/pipeline-2/) - Pipeline and products At MucosaTec GmbH, we are working at full speed on new and innovative drugs against influenza. We are also further evolving our platform technology to ensure it can be applied to other viruses in the future. Development pipline Drug candidates currently in development based on our adaptable platform technology: MT-AntiFlu The first
- [Investors](https://www.mucosatec.eu/investors/) - MucosaTec GmbH is actively seeking investors to advance our lead drug candidate into clinical testing. You can find our One Pager and our Pitch Deck by clicking on the links below. One Pager Pitch Deck
- [Pitch Deck](https://www.mucosatec.eu/pitch-deck/) - For a concise overview of our technology and collaboration opportunities, we invite you to review our Pitch Deck.
- [One Pager](https://www.mucosatec.eu/one-pager/) - MucosaTec GmbH is actively seeking investors to advance our lead drug candidate into clinical testing. Please see below for further details.
- [Company](https://www.mucosatec.eu/company/) - MucosaTec GmbH – the mucus engineering company Our mission is to enhance the protective properties of the mucus layer with our innovative concept, protecting people from respiratory infections. Our first product, a broadly effective nasal spray against various influenza viruses, is currently in the preclinical development phase. History of MucosaTec GmbH The COVID-19 pandemic has
- [A platform technology for broad-spectrum antivirals](https://www.mucosatec.eu/a-platform-technology-for-broad-spectrum-antivirals/) - A platform technology for broad-spectrum antivirals broad-spectrum antivirals antiviral platform technology Influenza prophylaxis and treatment The Issue The danger from airborne viruses is real and omnipresent. The COVID-19 pandemic has once again made this clear to us. Pandemics like these, especially those caused by influenza viruses, have already cost millions of lives in the past,
- [Contact](https://www.mucosatec.eu/contact/) - Contact us to get started MucosaTec GmbHAm Nußkopf 3966578 Schiffweiler Kontakt E-Mail: info@mucosatec.de
- [MucosaTec GmbH](https://www.mucosatec.eu/mucosatec-gmbh/) - MucosaTec GmbH – the mucus engineering company Our mission is to enhance the protective properties of the mucus layer with our innovative concept, protecting people from respiratory infections. Our first product, a broadly effective nasal spray against various influenza viruses, is currently in the preclinical development phase. History of MucosaTec GmbH The COVID-19 pandemic has
- [Privacy policy](https://www.mucosatec.eu/privacy-policy/) - Der verantwortungsvolle und rechtskonforme Umgang mit Ihren persönlichen Daten ist uns sehr wichtig. Deshalb informieren wir Sie an dieser Stelle umfassend und transparent, in welchen Fällen wir personenbezogene Daten von Ihnen verarbeiten und wie wir damit verfahren. 1. VERANTWORTLICHKEITVerantwortlich im Sinne der Datenschutz-Grundverordnung (DSGVO), sonstiger in den Mitgliedstaaten der Europäischen Union geltenden Datenschutzgesetze wie z.B.
- [Imprint](https://www.mucosatec.eu/imprint/) - Angaben gemäß § 5 TMG MucosaTec GmbHAm Nußkopf 3966578 Schiffweiler Kontakt E-Mail: info@mucosatec.de Geschäftsführer/in:Dr. Marius HittingerRegistergericht:HRB 109844, Gerichtsstand: Saarbrücken UmsatzsteuerUmsatzsteuer-Identifikationsnummer: DE364496987 FotonachweisDie auf dieser Website veröffentlichten Fotos haben folgende Copyrightangaben: © MucosaTec GmbH StreitschlichtungWir sind nicht bereit oder verpflichtet, an Streitbeilegungsverfahren vor einer Verbraucherschlichtungsstelle teilzunehmen. Haftung für InhalteAls Diensteanbieter sind wir gemäß § 7 Abs. 1

## 3D FlipBook

- [Investor Booklet V2](https://www.mucosatec.eu/3d-flip-book/investor-booklet-v1/)

## Real3D Flipbook

- [Pitchdek](https://www.mucosatec.eu/flipbook/pitchdek/)

## Categories

- [General](https://www.mucosatec.eu/category/general/)
- [Press](https://www.mucosatec.eu/category/press/)

## Tags

- [Influenza](https://www.mucosatec.eu/tag/influenza/)
- [Virus](https://www.mucosatec.eu/tag/virus/)
- [Antiviral](https://www.mucosatec.eu/tag/antiviral/)
- [SPRIN-D](https://www.mucosatec.eu/tag/sprin-d/)
- [Start-Up](https://www.mucosatec.eu/tag/start-up/)
- [Medication](https://www.mucosatec.eu/tag/medication/)
- [Antiviral Treatment](https://www.mucosatec.eu/tag/antiviral-treatment/)
- [Company](https://www.mucosatec.eu/tag/company/)